Hyperinsulinemia in Prediabetes Mediated by Interleukin-1β
Status:
Not yet recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical study is to test whether postprandial insulin secretion in subjects
with prediabetes is mediated by Interleukin-1β and may be influenced by administration of the
medicinal product anakinra (Kineret®).
The main question it aims to answer is whether there is a difference in insulin secretion
following a standardized mixed-meal test under anakinra compared to placebo.